INCY's Q3 Earnings & Revenues Beat Estimates on Higher Product SalesZacks Investment Research • 10/28/25
Incyte Falls After Hiked 2025 Outlook Misses Wall Street's Bullish ViewsInvestors Business Daily • 10/28/25
Incyte Reports Third Quarter 2025 Financial Results and Provides Business UpdatesBusiness Wire • 10/28/25
Incyte and Enable Injections Announce Strategic Partnership for enFuse® On-Body Delivery SystemBusiness Wire • 10/27/25
Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic DermatitisBusiness Wire • 10/25/25
Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trialPRNewsWire • 10/24/25
Incyte Corporation (INCY) Discusses ESMO Data on TGF-beta Receptor by PD-1 Bispecific in Colorectal Cancer and G12D Inhibitor in Pancreatic Cancer TranscriptSeeking Alpha • 10/20/25
Are You Looking for a Top Momentum Pick? Why Incyte (INCY) is a Great ChoiceZacks Investment Research • 10/20/25
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal AdenocarcinomaBusiness Wire • 10/19/25
Data from Incyte's TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 2025Business Wire • 10/12/25
China Medical System (867.HK; 8A8.SG) Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD IndicationGlobeNewsWire • 09/28/25